Assembly Biosciences, Inc.

NASDAQ:ASMB

Biotechnology

Healthcare
$22.50 +0.66%

+$0.16 today

Market cap
$460.74M
Beta
1.08
P/E (TTM)
-64.4
EPS (TTM)
-$0.38
52W Low $16.50High $39.71

Volume 0.33M

Average 0.17M

ASMB EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Assembly Biosciences, Inc.NASDAQ: ASMB

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$0.54, compared with -$1.17 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.58.

Context

  • EPS (Basic) grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 2 analysts of -$0.82 (-49.1%) for the fiscal year ending Dec 2026, a slowdown from the +91.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.54-121.7% QoQ
Last fiscal yearDec 2025
-$0.55+91.8% YoY
LTMMar 2026
-$0.58+90.9% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+53.8%+45.6%-8.3 pp
1 year+91.8%-49.1%-140.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(0.55) USD
Year-over-year change
+91.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How ASMB compares with its peers on the latest reported figures

  • ASMB's LTM Mar 2026 EPS (Basic) of -$0.58 is the 2nd highest of the 6 companies compared; the peer median is -$2.74.
  • Its year-over-year change of +90.9% is the 2nd highest of 6, against a peer median of +25.8%.
ASMB Competitors Peer median
EPS (Basic) for ASMB and competitors
Company Period LTM YoY 3-year CAGR
ABUSArbutus Biopharma CorporationLTM Mar 2026$0.83 +304.6%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026-$0.58 +90.9%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$2.11 -27.9%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$2.74 +39.6%—
VIRVir Biotechnology, Inc.LTM Mar 2026-$3.13 +25.8%—
INDPIndaptus Therapeutics, Inc.LTM Mar 2026-$6.34 -270.8%—
Peer median (excluding ASMB) -$2.74+25.8%—

Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.25M07.16M28.52M72.3M
Cost of Revenue069.08M48.9M55.93M129K
Gross Profit6.25M(69.08M)(41.74M)(27.41M)72.17M
Gross Margin100.0%—-582.7%-96.1%99.8%
Research & Development68.52M69.98M48.9M55.93M64.81M
Selling, General & Admin28.78M23.93M22.91M18.01M19.61M
Operating Expenses138.94M25.03M22.91M18.01M84.42M
Depreciation & Amortization466K498K450K129K129K
EBITDA(90.58M)(92.52M)(60.75M)(39.72M)(5.99M)
EBITDA Margin-1448.4%—-848.0%-139.3%-8.3%
Operating Income(132.69M)(94.11M)(64.65M)(45.42M)(12.12M)
Operating Margin-2121.7%—-902.5%-159.3%-16.8%
Interest Income302K1.02M3.45M5.57M6M
Interest Expense00000
Other Income / Expenses302K1.02M3.45M5.57M6M
Income Before Tax(132.39M)(93.09M)(61.2M)(39.85M)(6.12M)
Pre-Tax Margin-2116.8%—-854.3%-139.7%-8.5%
Income Tax Expense(2.53M)033K330K0
Net Income(129.86M)(93.09M)(61.23M)(40.18M)(6.12M)
Net Margin-2076.4%—-854.8%-140.9%-8.5%
EPS (Basic)(36.00)(22.82)(13.38)(6.69)(0.55)
EPS (Diluted)(36.00)(22.82)(13.38)(6.69)(0.55)
Weighted Avg Shares3.61M4.03M4.58M6M11.21M
Weighted Avg Shares (Diluted)3.61M4.03M4.58M6M11.21M

Assembly Biosciences, Inc.

NASDAQ:ASMB

Intrinsic Alpha fair value

Locked

Current Price

$22.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.